Supernus stock price target raised to $44 at TD Cowen
Supernus Pharmaceuticals (NASDAQ:SUPN) stock received a price target increase from TD Cowen, with the target moving up to $44.00 from the previous $43.00. The firm maintained a Buy rating on the ...
Supernus: New Approval Holds Promise Of Increased Growth
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
Wall Street Journal5d
Supernus Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE) and Supernus Pharmaceuticals (SUPN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report) and Supernus ...
Stock Traders Daily2d
How the (SUPN) price action is used to our Advantage
Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.
Nasdaq14d
SUPN Crosses Above Average Analyst Target
In recent trading, shares of Supernus Pharmaceuticals Inc (Symbol: SUPN) have crossed above the average analyst 12-month target price of $39.25, changing hands for $39.41/share. When a stock ...
Investing7d
Supernus stock surges on FDA approval
Supernus CEO Jack Khattar expressed the company's commitment to developing novel alternatives for managing neurological conditions. In response to the approval, TD Cowen analyst Stacy Ku, Ph.D. raised ...
Yahoo Finance16d
Supernus Pharmaceuticals, Inc. (SUPN)
If you buy and hold a stock for many years ... Knight entered into an agreement in December 2023 with Supernus Pharmaceuticals, ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus ...